Trexquant Investment’s Avita Medical RCEL Stock Holding History

Trexquant Investment’s Portfolio RCEL Stock Details RCEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-24,243	Closed	-$128K	–	1668
2022 Q3	$128K	Buy	+24,243	New	+$150K	﹤0.01%	1263

Other funds holding RCEL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Trexquant Investment's RCEL Position: Q4 2022 in Review

Trexquant Investment sold out of Avita Medical (RCEL) in Q4 2022, closing a stake of 24,243 shares — an estimated $128K sold.

Trexquant Investment first reported a position in RCEL in Q3 2022 and held it in 1 quarter. The position peaked at $128K in Q3 2022. 52 funds tracked by Wall St. Rank hold RCEL as of Q4 2022.

Trexquant Investment reported no remaining Avita Medical position as of Q4 2022 after selling out during the quarter.
Trexquant Investment sold 24,243 Avita Medical shares in Q4 2022, an estimated $128K.
Trexquant Investment first reported a position in Avita Medical in Q3 2022 and held it in 1 quarter.
Trexquant Investment's Avita Medical position peaked at $128K in Q3 2022.
52 funds tracked by Wall St. Rank held Avita Medical as of Q4 2022.

Based on Trexquant Investment's 13F filing for Q4 2022, filed 13 Feb 2023.